Didier Bruno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Didier Bruno has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Ana Garcia-Reyne
Hospital 12 de Octubre, Madrid, Spain
2 shared publicationsCarlos M. Luna
2 shared publications- Emilio Bouza
Department of Clinical Microbiology and Infectious Diseases; Gregorio Marañón Institute of Health Research (IiSGM); Department of Medicine, Faculty of Medicine, Complutense University. Madrid, Spain
2 shared publications George T. John
Christian Medical College Hospital, Vellore, India
2 shared publications- Hsin-Yun Sun
Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
2 shared publications Jose M. Aguado
Hospital 12 de Octubre, Madrid, Spain
2 shared publications
Latest Publications
- 1 March 2014
- Published by SAGE Publications in Progress in Transplantation
- Vol. 24 (1) , 37-43
Tuberculosis in Solid-Organ Transplant Recipients: Disease Characteristics and Outcomes in the Current Era
We determined the characteristics of posttransplant tuberculosis and the impact of rifampin-based antituberculosis regimens on outcomes in the current era. Patients comprised 64 transplant recipients with tuberculosis, divided into 2 consecutive cohorts: an earlier cohort (cases occurring from 2003 to 2007) and a later cohort (cases from 2008 to 2011). Patients from the later versus earlier era had tuberculosis develop later after transplant (odds ratio, 1.01; 95% CI, 1.00–1.02; P = .05), were more likely to be liver transplant recipients (odds ratio, 4.52; 95% CI, 1.32–15.53; P = .02), and were more likely to receive tacrolimus-based immunosuppression (odds ratio, 3.24; 95% CI, 1.14–9.19; P = .03). Mortality rate was 10% in the later cohort and 21% in the earlier cohort ( P = .20). Rifampin-based treatment was less likely to be used in patients with prior rejection ( P = .04). However, neither rejection rate ( P = .71) nor mortality ( P = .93) after tuberculosis differed between recipients who received rifampin and recipients who did not. Thus, notable changes have occurred in the epidemiological characteristics of tuberculosis in transplant recipients. Overall mortality rate has improved, with about 90% of the patients now surviving after tuberculosis.
- 1 March 2014
- Published by SAGE Publications in Progress in Transplantation
- Vol. 24 (1) , 37-43
Tuberculosis in Solid-Organ Transplant Recipients: Disease Characteristics and Outcomes in the Current Era
We determined the characteristics of posttransplant tuberculosis and the impact of rifampin-based antituberculosis regimens on outcomes in the current era. Patients comprised 64 transplant recipients with tuberculosis, divided into 2 consecutive cohorts: an earlier cohort (cases occurring from 2003 to 2007) and a later cohort (cases from 2008 to 2011). Patients from the later versus earlier era had tuberculosis develop later after transplant (odds ratio, 1.01; 95% CI, 1.00–1.02; P = .05), were more likely to be liver transplant recipients (odds ratio, 4.52; 95% CI, 1.32–15.53; P = .02), and were more likely to receive tacrolimus-based immunosuppression (odds ratio, 3.24; 95% CI, 1.14–9.19; P = .03). Mortality rate was 10% in the later cohort and 21% in the earlier cohort ( P = .20). Rifampin-based treatment was less likely to be used in patients with prior rejection ( P = .04). However, neither rejection rate ( P = .71) nor mortality ( P = .93) after tuberculosis differed between recipients who received rifampin and recipients who did not. Thus, notable changes have occurred in the epidemiological characteristics of tuberculosis in transplant recipients. Overall mortality rate has improved, with about 90% of the patients now surviving after tuberculosis.
- 15 May 2013
- Published by Wolters Kluwer Health in Transplantation
- Vol. 95 (9) , 1173-1181
Mycobacterium Tuberculosis—Associated Immune Reconstitution Syndrome in Solid-Organ Transplant Recipients
Incidence, characteristics, and risk factors for tuberculosis (TB)-associated immune reconstitution inflammatory syndrome (IRS) in solid-organ transplant (SOT) recipients are not known. Patients are composed of 64 consecutive SOT recipients with TB followed for 12 months. IRS was defined based on previously proposed criteria. IRS developed in 14% (9/64) of the patients, a median of 47 days after the use of anti-TB therapy. Liver versus other types of organ transplant recipients (adjusted odds ratio [OR], 6.11; 95% confidence interval [CI], 1.08–34.86), prior cytomegalovirus infection (adjusted OR, 5.65; 95% CI, 0.93–34.47), and rifampin use (adjusted OR, 4.56; 95% CI, 0.74–27) were associated with a higher risk of IRS. The presence of more than one factor (liver transplantation, cytomegalovirus infection, and rifampin use) when compared with none of these factors conferred a 19-fold increase in the risk of IRS (P=0.01). Mortality at 1 year after diagnosis was 33.3% in patients with IRS and 17.2% in those without IRS (P=0.31). IRS was documented in 14% of the SOT recipients with TB. We determined clinically identifiable factors that may be useful in assessing the risk of tuberculosis-associated posttransplantation IRS.
- 15 May 2013
- Published by Wolters Kluwer Health in Transplantation
- Vol. 95 (9) , 1173-1181
Mycobacterium Tuberculosis—Associated Immune Reconstitution Syndrome in Solid-Organ Transplant Recipients
Incidence, characteristics, and risk factors for tuberculosis (TB)-associated immune reconstitution inflammatory syndrome (IRS) in solid-organ transplant (SOT) recipients are not known. Patients are composed of 64 consecutive SOT recipients with TB followed for 12 months. IRS was defined based on previously proposed criteria. IRS developed in 14% (9/64) of the patients, a median of 47 days after the use of anti-TB therapy. Liver versus other types of organ transplant recipients (adjusted odds ratio [OR], 6.11; 95% confidence interval [CI], 1.08–34.86), prior cytomegalovirus infection (adjusted OR, 5.65; 95% CI, 0.93–34.47), and rifampin use (adjusted OR, 4.56; 95% CI, 0.74–27) were associated with a higher risk of IRS. The presence of more than one factor (liver transplantation, cytomegalovirus infection, and rifampin use) when compared with none of these factors conferred a 19-fold increase in the risk of IRS (P=0.01). Mortality at 1 year after diagnosis was 33.3% in patients with IRS and 17.2% in those without IRS (P=0.31). IRS was documented in 14% of the SOT recipients with TB. We determined clinically identifiable factors that may be useful in assessing the risk of tuberculosis-associated posttransplantation IRS.
- 1 September 2011
- Published by European Respiratory Society (ERS)
Animal models of VAP
- 1 September 2010
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 38 (9) , 1910-1912
Vancomycin, unbeatable for methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia? Really?*
- 1 September 2010
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 38 (9) , 1910-1912
Vancomycin, unbeatable for methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia? Really?*
- 1 February 2009
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 37 (2) , 779-780
Role for bacteriophages in the preparedness for fighting against pneumonia in the postantibiotic era*
- 1 February 2009
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 37 (2) , 779-780
Role for bacteriophages in the preparedness for fighting against pneumonia in the postantibiotic era*